These mechanisms comprise inhibition of Fscn1-dependent tumor cell migration [19,20,21,48] and Fscn1-dependent gene expression in tumor cells [18,49,50,51], which may impact the characteristics of the TME, e.g., via soluble mediators. The gene discussed is FSCN1; the disease is neoplasm.